PRTN3 and type 1 diabetes mellitus: Thus, our studies do not support or discount the possibility that increasing TEX with therapy improves outcome (decreases disease activity, ACPA or rheumatoid factor levels) in RA as has been shown in T1D with teplizumab (anti-CD3) therapy (12, 13).